UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 18, 2010

 

 

Endo Pharmaceuticals Holdings Inc.

(Exact name of registrant as specified in its charter)

 

 

 

DELAWARE		001-15989		13-4022871
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

100 Endo Boulevard

Chadds Ford, Pennsylvania 19317

(Address of principal executive offices, including zip code)

(610) 558-9800

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

Item 7.01.

Regulation FD Disclosure.

Endo Pharmaceuticals Holdings Inc. (“Endo,” the “Company,” “we,” “us” or “our”) is furnishing under Item 7.01 of this Current Report on Form 8-K certain information with respect to Endo that has not previously been reported to the public. This information is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth in such filing.

 

Item 8.01.

Other Events

On November 18, 2010, Endo Pharmaceuticals Holdings Inc. issued a press release announcing the pricing of its private offering of $400 million aggregate principal amount of 7.00% senior unsecured notes due 2020. A copy of this press release is filed herewith as Exhibit 99.2 and incorporated herein by reference.

The notes and the related guarantees have not been registered under the Securities Act of 1933, as amended, and may not be offered in the United States absent registration or an applicable exemption from registration requirements.

 

Item 9.01.

Financial Statements and Exhibits

 

(d)

Exhibits

 

99.1

Certain information with respect to Endo that has not previously been reported to the public.

 

99.2

Press Release of Endo Pharmaceuticals Holdings Inc., dated November 18, 2010.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 18, 2010

---

Index to Exhibits

 

Exhibit Number		Description
99.1		Certain information with respect to Endo that has not previously been reported to the public.
99.2		Press Release of Endo Pharmaceuticals Holdings Inc., dated November 18, 2010.